Gynecologic Cancer Funded
Funded research to save lives
2024 | Mt. Baker Climb | $33,000 Raised
Ovarian Cancer Early Detection Research
$25,000
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Creative Ovarian Cancer Awareness
$8,000
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
2023 | Mt. Everest Climb | $300,000 Raised
TUBA-WISP II Trial
MOCA is distributing funds raised by the Any Mountain trek to Mt. Everest to cancer centers throughout the U.S. to support the expansion of the international TUBA-WISP II trial. This surgical prevention trial, managed by MD Anderson Cancer Center, gives women, who are at high risk for ovarian cancer due to genetic mutations, the option of a two-step procedure to reduce their risk. By having their fallopian tubes surgically removed first (salpingectomy) with a delayed ovary removal (oophorectomy), women are able to preserve hormonal function longer, thereby maintaining cardiovascular protection, sexual function and other benefits.
The Any Mountain funding is being used to open sites across the country expanding access to diverse populations.
The Any Mountain TUBA-WISP II trial is currently open and enrolling patients at:
- MD Anderson (Houston, Texas)
- Mayo Clinic (Rochester, MN)
- Memorial Sloan Kettering (New York City)
- University of Washington (Seattle)
- Dana Farber Cancer Institute (Boston)
- Wahington University (St. Louis)
- Mount Sinai (NYC)
- University of Pennsylvania (Philadelphia)
For more information about the trial:
2021 | $125,000 Raised
The following research projects were approved for one year of funding by Any Mountain in October 2021 and are currently underway.
TUBA-WISP II Study
$65,000
Principal Investigator: Karen Lu, MD at MD Anderson, Houston, TX
The TUBA-WISP II Study is a world-wide prevention study in high-risk women with multiple centers in the United States. This trial is designed to determine whether removing the fallopian tubes and delaying ovarian removal by 5 years is effective for reducing hereditary ovarian cancer risk, which would allow women to keep their ovarian function intact for a longer period of time. Women self-select whether they want to undergo a standard removal of ovaries and fallopian tubes in one surgery or a new option to remove only the fallopian tubes and some years later remove the ovaries. Any Mountain funds will be used to finalize data forms, set up the national database, assist sites with IRB submissions and begin patient enrollment. Data from similar studies being done in other countries around the world will be pooled together to determine how safe and effective the new prevention option is for high risk women. Data from this trial could change the standard care for women at high risk of ovarian cancer
Understanding Decision Making For Risk Reducing Surgery
$30,000
Principal Investigator: Kara Long Roche, MD at Memorial Sloan Kettering, NYC
This study will identify common themes and influential factors in the decision to undergo risk-reducing removal of the tubes and ovaries in young women at high genetic risk of developing ovarian cancer. The researchers will determine sociodemographic, medical, and psychosocial factors that contribute to the decision-making process. Data from this study will help us better counsel women about options for managing an increased risk of ovarian cancer.
Predictor Of Completion Of Genetic Testing: An Ancillary Analysis Of The Magenta Study
$30,000
Principal Investigator: Barbara Norquist, MD at University of Washington, Seattle
THE MAGENTA study was a large trial that evaluated how much genetic counseling was needed to deliver testing for cancer genetic risk to women in their homes. This ancillary analysis of the MAGENTA study will help us better understand why some people start the process, but then do not complete genetic testing at home by interviewing women who did and did not complete the testing process. Results from this study will help us identify concerns and barriers to genetic testing for cancer risk and inform future interventions to bring risk assessment to more people.
Our Research
The Any Mountain project is made possible by Let Every Woman Know – Alaska and the Minnesota Ovarian Cancer Alliance.
Let Every Woman Know – Alaska
Let Every Woman Know – Alaska is dedicated to raising awareness, sharing information and saving lives by educating people in the Last Frontier and supporting women living with gynecologic cancers. It’s an Alaska-based non-profit, founded by Dr. Joanie Hope, which provides creative state-wide education, support, advocacy, and arts programs unique to the state’s diverse communities.
Minnesota Ovarian Cancer Alliance
The Minnesota Ovarian Cancer Alliance (MOCA) is one of our key partners and committed to responsibly managing the funds raised for ovarian cancer research through the Any Mountain project. MOCA is a 501(c)3 non-profit organization dedicated to funding ovarian cancer research, providing support to the women and families affected by ovarian cancer, educating the medical community, and raising awareness of ovarian cancer.
Join the Climb
Lorem ipsum odor amet, consectetuer adipiscing elit. Morbi dolor primis inceptos adipiscing gravida in. Litora habitant pulvinar nibh; nisi ex fringilla praesent. Morbi ultrices vehicula felis rutrum vehicula. Ullamcorper blandit vulputate aptent integer viverra proin integer sociosqu.
Apply for Research Funding
Lorem ipsum odor amet, consectetuer adipiscing elit. Morbi dolor primis inceptos adipiscing gravida in. Litora habitant pulvinar nibh; nisi ex fringilla praesent. Morbi ultrices vehicula felis rutrum vehicula. Ullamcorper blandit vulputate aptent integer viverra proin integer sociosqu.